BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer:

Introduction:BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK pathway signaling...